| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2) |
| Entrez GeneID | 3593; |
| WB Predicted band size | 40kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide from human protein at AA range: 241-290 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于IL-12B p40抗体的参考文献概述，按领域分类整理：
---
### **基础机制研究**
1. **文献名称**：*Interleukin-12 and the regulation of innate resistance and adaptive immunity*
**作者**：Trinchieri G.
**摘要**：阐述IL-12家族(含IL-12和IL-23)中p40亚基的结构与功能，强调其通过结合受体调控Th1细胞分化及抗感染免疫的作用。
2. **文献名称**：*Novel p19 protein engages IL-12p40 to form a cytokine, IL-23. with biological activities similar as well as distinct from IL-12*
**作者**：Oppmann B. et al.
**摘要**：首次发现IL-12B p40与IL-23 p19结合形成IL-23.揭示p40亚基在IL-12/IL-23双通路中的核心地位。
---
### **疾病治疗应用**
3. **文献名称**：*Anti-IL-12/23p40 antibodies for the treatment of plaque psoriasis*
**作者**：Leonardi C. et al.
**摘要**：临床试验证实抗p40单抗(如Ustekinumab)通过阻断IL-12/IL-23通路显著改善银屑病症状，验证p40作为治疗靶点的可行性。
---
### **动物模型研究**
4. **文献名称**：*Role of IL-12p40 in experimental autoimmune encephalomyelitis*
**作者**：Segal B.M. et al.
**摘要**：在小鼠EAE模型(多发性硬化模型)中，p40抗体通过抑制Th17和Th1细胞分化减轻神经炎症，提示其治疗潜力。
---
**提示**：若需具体实验方法或最新研究，可进一步提供方向(如肿瘤免疫、特定疾病模型)。
**Background of IL-12B p40 Antibody**
IL-12B p40 is a subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), two heterodimeric cytokines critical in regulating immune responses. IL-12. composed of IL-12A (p35) and IL-12B (p40), promotes Th1 differentiation and interferon-gamma (IFN-γ) production, while IL-23 (p19/p40) sustains Th17-mediated inflammation. Antibodies targeting IL-12B p40 block both IL-12 and IL-23 signaling, making them valuable tools for studying and modulating immune pathways.
Therapeutic anti-IL-12B p40 monoclonal antibodies, such as ustekinumab, have been developed to treat autoimmune diseases like psoriasis, psoriatic arthritis, and Crohn’s disease. By neutralizing p40. these antibodies inhibit downstream proinflammatory cytokine production, reducing pathological inflammation. Clinical trials demonstrate their efficacy in suppressing disease activity with favorable safety profiles.
In research, IL-12B p40-specific antibodies are used to dissect the roles of IL-12 and IL-23 in infection, autoimmunity, and cancer. They help elucidate mechanisms of immune cell crosstalk, cytokine redundancy, and therapeutic targeting. Structural studies reveal that p40 antibodies prevent receptor binding by disrupting heterodimer stability.
Overall, IL-12B p40 antibodies bridge basic immunology and clinical translation, offering insights into cytokine biology and providing targeted therapies for immune-mediated disorders. Their dual inhibition of IL-12 and IL-23 highlights the complexity of cytokine networks and the potential for broad-spectrum immunomodulation.
×
